Health-care companies rose after a breakthrough at the intersection of vaccines and oncology.
An experimental mRNA-based vaccine succeeded in preventing cancer from coming back or spreading in a study of high-risk melanoma patients, Moderna and its partner Merck said Wednesday, paving the way for a potentially new life-extending treatment for the thousands of people diagnosed with the deadly skin cancer each year.
Moderna shares more than doubled while Merck's rose by 10%.
Shares of obesity-drug maker Eli Lilly continued a recent rally.
Write to Rob Curran at rob.curran@dowjones.com
